Alkermes plc. Remaining Share Repurchase Authorization
Alkermes plc. (ALKS) had Remaining Share Repurchase Authorization of $172.30 million as of 2026-06-30, per its 10-Q filed 2026-07-28.
Financial Statements › Notes › Equity
us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1 · last filed 2026-07-28
- 2026-06-30: Stock Repurchase Program, Remaining Authorized Repurchase Amount $172.30M.
- 2026-03-31: Stock Repurchase Program, Remaining Authorized Repurchase Amount $172.30M.
- 2025-12-31: Stock Repurchase Program, Remaining Authorized Repurchase Amount $200.00M.
- 2025-09-30: Stock Repurchase Program, Remaining Authorized Repurchase Amount $200.00M.
| Period end | Stock Repurchase Program, Remaining Authorized Repurchase Amount |
|---|---|
| 2026-06-30 | $172.30M 10-Q · filed 2026-07-28 |
| 2026-03-31 | $172.30M 10-Q · filed 2026-05-05 |
| 2025-12-31 | $200.00M 10-K · filed 2026-02-25 |
| 2025-09-30 | $200.00M 10-Q · filed 2025-10-28 |
| 2025-06-30 | $200.00M 10-Q · filed 2025-07-29 |
| 2025-03-31 | $200.00M 10-Q · filed 2025-05-01 |
| 2024-12-31 | $200.00M 10-K · filed 2025-02-12 |
| 2024-09-30 | $200.00M 10-Q · filed 2024-10-24 |
| 2024-06-30 | $315.30M 10-Q · filed 2024-07-24 |
| 2022-12-31 | $101.00M 10-K · filed 2023-02-16 |
| 2021-12-31 | $101.00M 10-K · filed 2022-02-16 |
| 2020-12-31 | $101.00M 10-K · filed 2021-02-11 |
| 2019-12-31 | $101.00M 10-K · filed 2020-02-13 |
| 2018-12-31 | $101.00M 10-K · filed 2019-02-15 |
| 2017-12-31 | $101.00M 10-K · filed 2018-02-16 |
| 2016-12-31 | $101.00M 10-K · filed 2017-02-17 |
| 2015-12-31 | $101.00M 10-K · filed 2016-02-25 |
| 2014-12-31 | $101.00M 10-K · filed 2015-02-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |